



What We are talking About (and Not Talking About)

Our Topic

- Multiple myeloma
- Autologous stem cell transplant
- Transplant as part of treatment for newly diagnosed myeloma
- Maintenance therapy



BMT infonet.org


Other Topics

- Lymphoma, leukemia, amyloidosis, smoldering myeloma
- Allogeneic (donor) stem cell transplant
- Transplant as treatment for relapsed or refractory myeloma
- Consolidation therapy


2023 SURVIVORSHIP SYMPOSIUM


Myeloma Diagnosis

- Cancer of malignant plasma cells
- Diagnosed by finding
 - clonal plasma cells in the bone marrow
 - abnormal antibody proteins in the blood and urine



2023 SURVIVORSHIP SYMPOSIUM







2023 SUBVIVORSHIP SYMPOSIUM


Available Treatments for Myeloma

- Steroids (dexamethasone, prednisone)
- IMiDs (lenalidomide, pomalidomide, thalidomide)
- Proteasome inhibitors (bortezomib, carfilzomib, ixazomib)
- Antibodies (daratumumab, isatuximab, elotuzumab)
- Cytotoxics (cyclophosphamide, melphalan, doxorubicin)
- Newer agents (selinexor, venetoclax)
- CAR T cells (ide-cel, cilta-cel)
- T cell engagers (teclistamab)

BMT infonet.org







Maintenance Treatments with Proven Benefit in Myeloma

Lenalidomide (Revlimid)

- 4 randomized clinical trials comparing Len to placebo or no treatment
- Improved overall survival (even though Len was available at progression)
- Confirmed in a meta-analysis combining trial data

Bortezomib (Velcade)

- 1 randomized clinical trial of bortezomib pre-transplant and in maintenance, compared to thalidomide-based treatment
- Improved overall survival

2023 SURVIVORSHIP SYMPOSIUM

Other Maintenance Treatments That Have Been Tried in Myeloma

Not commonly used

• steroids

BMT infonet.org

30 YEARS

BMTinfonet.org

- thalidomide (Thalomid)
- ixazomib (Ninlaro)

(these have had clinical trials showing limited or no benefit)

Used in some situations

- Lenalidomide combinations
 - + bortezomib
 - + carfilzomib
 - + daratumumab
- Pomalidomide (alone or in combination)

(these have limited data but possible benefit)

2023 SURVIVORSHIP SYMPOSIUM

